Precision intrauterine contraception may significantly increase continuation of use: A review of long-term clinical experience with frameless copper-releasing intrauterine contraception devices

International Journal of Women's Health

Volumn 5, Issue 1, 2013, Pages 215-225

  Wildemeersch, Dirk ^a   Pett, Ansgar ^b   Jandi, Sohela ^b   Hasskamp, Thomas ^c   Rowe, Patrick ^d   Vrijens, Marc ^e  

^a Outpatient and IUD Training Clinic   (Belgium)

^b Outpatient Clin Ctr Gynecol O   (Germany)

^c Oncologic Outpatient Clinics   (Germany)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e Gynecological Outpatient Clinic   (Belgium)

Author keywords

Anchored IUS; Frameless IUS; GyneFix; Tolerance, acceptability, continuation, discontinuation

Indexed keywords

LEVONORGESTREL;

ACCURACY; ADOLESCENT; ADULT; AGE; CLINICAL RESEARCH; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; ENDOMETRIUM; EXPERIENCE; FEMALE; HUMAN; INDUCED ABORTION; INTRAUTERINE CONTRACEPTIVE DEVICE; MAJOR CLINICAL STUDY; MENSTRUATION; NULLIPARA; PARITY; PELVIS PAIN SYNDROME; REVIEW; UNSPECIFIED SIDE EFFECT; UNWANTED PREGNANCY; UTERUS;

EID: 84877011835     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/IJWH.S42784     Document Type: Review

References (60)

1. Blumenthal P, Voedisch A, Gemzell-Danielsson K. Strategies to prevent unintended pregnancy: increasing use of long-acting reversible contraception. Hum Reprod Update. 2011;17:121-137.
2. LiveStrong.com [webpage on the Internet]. Teen pregnancy rates in the USA. 2011. Available from: http://www.livestrong.com/article/12504teen-pregnancy-rates-usa. Accessed January 17, 2012.
3. Trussell J. Contraceptive failure in the United States. Contraception. 2011;83:397-404.
4. Goodman S, Hendlish SK, Reeves MF, Foster-Rosales A. Impact of immediate post-abortal insertion of intrauterine contraception on repeat abortion. Contraception. 2008:78;143-148.
5. Cleland K, Zhu H, Goldstuck N, Cheng L, Trussell J. The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience. Hum Reprod. 2012;27:1994-2000.
6. Trussell J, Lalla AM, Doan QV, Reyes E, Pinto L, Gricar J. Cost effectiveness of contraceptives in the United States. Contraception. 2009;79:5-14.
7. Hasson HM. Clinical studies of the Wing Sound II metrology device. In: Zatuchni GI, Goldsmith A, Sciarra JJ, editors. Intrauterine Contraception: Advances and Future Prospects. Philadelphia: Harper and Row; 1984:126-141.
8. Kurz KH. Cavimeter uterine measurements and IUD clinical correlation. In: Zatuchni GI, Goldsmith A, Sciarra JJ, editors. Intrauterine Contraception: Advances and Future Prospects. Philadelphia: Harper and Row; 1984:142-162.
9. Kamal I, Hefnawi F, Ghonheim M, Talant M, Abdalla M. Dimensional and architectural disproportion between the intrauterine device and the uterine cavity: a cause of bleeding. Fert Steril. 1971;22:514-521.
10. Roy S, Cooper D, Mishell DR. Experience with three different models of the Copper T intrauterine contraceptive device in nulliparous women. Am J Obstet Gynecol. 1974;119(3):414-417.
11. Gadelha Da Costa A, Filho FM, Ferreira AC, Spara P, Mauad FM. Uterine volume in adolescents. Ultrasound Med Biol. 2004;30: 7-10.
12. Bulletti C, de Ziegler D, Polli V, Diotalle L, Del Ferro E, Flamigni C. Uterine contractility during the menstrual cycle. Hum Reprod. 2000; 15 Suppl 1:81-89.
13. Petersen KR, Brooks L, Jacobsen B, Skouby SO. Intrauterine devices in nulliparous women. Adv Contracept. 1991;7:333-338.
14. Canteiro R, Bahamondes V, dos Santos Fernandes A, Espejo-Arce X, Marchi NM, Bahamondes L. Length of the endometrial cavity as measured by uterine sounding and ultrasonography in women of different parities. Contraception. 2010;81:515-519.
15. Zohav E, Anteby EY, Orvieto R. Use of three-dimensional ultrasound in evaluating the intrauterine position of a levonorgestrel-releasing intrauterine system. Reprod Biomed Online. 2007;14:495-497.
16. Benacerraf BR, Shipp TD, Lyons JG, Bromley B. Width of the normal uterine cavity in premenopausal women and effect of parity. Obstet Gynecol. 2010;116(2 Pt 1):305-310.
17. Wildemeersch D, Van der Pas H, Thiery M, Van Kets H, Parewijck W, Delbarge W. The Copper-Fix (Cu-Fix): a new concept in IUD t{stroke}echnology. Adv Contracept. 1988;4:197-205.
18. Van Kets H, Vrijens M, Van Trappen Y, et al. The frameless GyneFix intrauterine implant: a major improvement in efficacy, expulsion and tolerance. Adv Contracept. 1995;11:131-142.
19. Wu S, Hu J, Wildemeersch D. Performance of the frameless GyneFix and the TCu380A IUDs in a three-year multicenter randomized comparative trial in parous women. Contraception. 2000;61:91-98.
20. Wildemeersch D, Andrade A. Commentary - A historical note on the development of the frameless IUD. Contraception. 2010;81: 172-176.
21. Cao X, Zhang W, Zhao X, et al. Three-year efficacy and acceptability of the GyneFix 200 intrauterine device. Contraception. 2004;69:207-211. Erratum. Contraception. 2006;73:315-317.
22. 2 and users of a copper-levonorgestrel-releasing intrauterine system. Contraception. 2004;70:169-172.
23. Batár I, Wildemeersch D, Vrijens M, Delbarge W, Temmerman M, Gbolade BA. Preventing abortion and repeat abortion with the GyneFix intrauterine implant system - preliminary results. Adv Contracept. 1998;14(2):91-96.
24. Gbolade BA. Immediate insertion of the postabortion version of the GyneFix intrauterine implant system. Contemp Rev Obstet Gynaecol. 1999;11:29-33.
25. Martinez F, Gimenez E, Hernandez G, et al. Experience with GyneFix insertions in Spain: favorable acceptance of the intrauterine contraceptive implant with some limitations. Contraception. 2002;66: 315-320.
26. Wildemeersch D. The force required to remove the frameless 0-suture anchoring system: comparison between pre-and postmenopausal women. Contraception. 2004;69:513-515.
27. Trussell J. Contraceptive failure in the United States. Contraception. 2011;83:397-404.
28. Winner B, Peipert JF, Zhao Q, et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012;366:1998-2007.
29. Stuart JE, Secura GM, Zhao Q, Pittman ME, Peipert JF. Factors associated with 12-month pill, patch, and ring users. Obstet Gynecol. 2013;121:330-336.
30. Finer LB, Jerman J, Kavanaugh ML. Changes in use of long-acting contraceptive methods in the United States, 2007-2009. Fertil Steril. 2012;98:893-897.
31. Haimovich S. Prof ile of long-acting reversible contraception users in Europe. Eur J Contracept Reprod Health Care. 2009;14: 187-195.
32. Secura GM, Allsworth JE, Madden T, Mullersman JL, Peipert JF. The Contraceptive CHOICE Project: reducing barriers to long-acting reversible contraception. Am J Obstet Gynecol. 2010;203:115.e1-e7.
33. Mestad R, Secura G, Allsworth JE, Madden T, Zhao Q, Peipert JF. Acceptance of long-acting reversible contraceptive methods by adolescent participants in the Contraceptive CHOICE Project. Contraception. 2011;84:493-498.
34. Wellings K, Zhihong Z, Krentel A, Barrett G, Glasier A. Attitudes towards long-acting reversible methods of contraception in general practice in the UK. Contraception. 2007;76:208-214.
35. Kaunitz A. Changing the contraceptive paradigm: making long-acting methods the default option. Medscape Today. 2012. Available from: http://www.medscape.com/viewarticle/765969. Accessed March 4, 2013.
36. Trussell J, Henry N, Hassan F, Prezioso A, Law A, Filonenko A. Burden of unintended pregnancy in the United States: potential savings with increased use of long-acting reversible contraception. Contraception. 2013;87:154-161.
37. American Congress of Obstetricians and Gynecologists. Committee opinion number 539: Adolescents and long-acting reversible contraception: implants and intrauterine devices. 2012. Available from: http://www.acog.org/Resources%20And%20Publications/Committee%20Opinions/Committee%20on%20Adolescent%20Health%20Care/Adolescents%20and%20Long-Acting%20Reversible%20Contraception.aspx. Accessed March 4, 2013.
38. Blumenthal PD, Gemzell-Danielsson K, Marintcheva-Petrova M. Tolerability and clinical safety of Implanon. Eur J Contracept Reprod Health Care. 2008;13 Suppl 1:29-36.
39. Lyus R, Lohr P, Prager S. Use of Mirena LNG-IUS and Paragard CuT380A intrauterine devices for nulliparous women. Contraception. 2010;81:367-371.
40. Bahamondes MV, Hidalgo MM, Bahamondes L, Monteiro I. Ease of insertion and clinical performance of the levonorgestrel-releasing intrauterine system in nulligravidas. Contraception. 2011; 84:e11-e6.
41. Marions L, Lövkvist L, Taube A, Johansson M, Dalvik H, Øverlie I. Use of the levonorgestrel releasing-intrauterine system in nulliparous women - a non-interventional study in Sweden. Eur J Contracept Reprod Health Care. 2011;16:126-134.
42. Hubacher D. Copper intrauterine device used by nulliparous women:review of side effects. Contraception. 2007;75:S8-S11.
43. Paterson H, Ashtin J, Harisson-Woolrych. A nationwide cohort study of the use of the levonorgestrel intrauterine device in New Zealand adolescents. Contraception. 2009;79:433-438.
44. Suhonen S, Haukkamaa M, Jakobsson T, Rauramo I. Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study. Contraception. 2004;69:407-412.
45. Andersson K, Odlind V, Rybo G. Levonorgestrel releasing and copper releasing (Nova T) IUCDs during five years of use. A randomized comparative study. Contraception. 1994;49:56-72.
46. Luukkainen T, Allonen H, Haukkamaa M, et al. Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study. Contraception. 1987;36:160-179.
47. Rivera R, Chen-Mok M, McMullen S. Analysis of client characteristics that may affect early discontinuation of the TCu-380A IUD. Contraception. 1999;60:155-160.
48. Teal SB, Sheeder J. IUD use in adolescent mothers: retention, failure and reasons for discontinuation. Contraception. 2012;85:270-274.
49. Benacerraf BR, Shipp TD, Bromly B. Three-dimensional ultrasound detection of abnormally located intrauterine contraceptive devices which are the source of pelvic pain and abnormal bleeding. Ultrasound Obstet Gynecol. 2009;34:110-115.
50. Braaten KP, Benson CB, Maurer R, Goldberg AB. Malpositioned intrauterine contraceptive devices: risk factors, outcomes, and future pregnancies. Obstet Gynecol. 2011;118:1014-1020.
51. Andrade CMA, Barbieri M, Nowak PM, Torloni MR, Araujo FF, Guazzelli CAF. Is three-dimensional ultrasound better for the identification of the levonorgestrel intrauterine system? 12th Congress of the European Society of Contraception and Reproductive Health Care; Athens, Greece; June 22-23, 2012.
52. Wildemeersch D. The effective copper surface area differs substantially between that of the frameless copper IUD and that of conventional copper IUDs: a comment. J Fam Plann Reprod Health Care. 2006; 32:54.
53. Andrade TL, Andrade MD, Pizzaro Orchard E. Quantitative studies on menstrual blood loss in IUD users. Contraception. 1987;36:129-144.
54. [No authors listed]. The TCu380A IUD and the frameless "FlexiGard", interim three-year data from an international multicenter trial. UNDP, UNFPA, and WHO Special Programme of Research, Development and Research Training in Human Reproduction, World Bank: IUD Research Group. Contraception. 1995;52:77-83.
55. Milsom I, Rybo G, Lindstedt G. The influence of copper surface area on menstrual blood loss and iron status in women fitted with an IUD. Contraception. 1990;41:271-281.
56. Sivin I, Shaaban M, Odlind V, et al. A randomized trial of the Gyne T 380 and Gyne T 380 Slimline intrauterine copper devices. Contraception. 1990;42:379-389.
57. Andersson K, Odlind V, Rybo G. Levonorgestrel releasing and copper releasing (Nova T) IUCDs during five years of use. A randomized comparative study. Contraception. 1994;49:56-72.
58. Sivin I, el Mahgoub S, McCarthy T, et al. Long-term contraception with the levonorgestrel 20mcg/day (LNg 20) and the copper T 380Ag intrauterine devices: a five-year randomized study. Contraception. 1990;42:361-378.
59. Vickery Z, Madden T. Difficult intrauterine contraception insertion in a nulligravid patient. Obstet Gynecol. 2011;117:391-395.
60. Faculty of Sexual and Reproductive Healthcare, data on file, FSRH Clinical Effectiveness Unit (2009).